statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. (NASDAQ:NVCT  Free Report)  Stock analysts at Roth Capital upped their FY2028 earnings estimates for Nuvectis Pharma in a research note issued on Thursday...

FY2028 Earnings Estimate for Nuvectis Pharma, Inc. Issued By Roth Capital (NASDAQ:NVCT)

33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating...

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16...

Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16

NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the...

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Volume	30,633.00
52-Wk High	$18.65
52-Wk Low	$5.92

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.40	--	--	N/A
Q4'23	-$0.41	-$0.41	--	EXPECTED
Q3'23	-$0.34	-$0.37	-8.04%	MISSED
Q2'23	-$0.29	-$0.38	-30.23%	MISSED
Q1'23	-$0.44	-$0.27	38.80%	BEAT

NVCT Nuvectis Pharma Inc

About

Feed

News

Earnings

Fundamentals